{"schema_version":"secwatch.filing_event.v1","accession":"0001516551-24-000008","form_type":"8-K","ticker":"SKYE","cik":"0001516551","company_name":"Skye Bioscience, Inc.","filed_at":"2024-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.457336+00:00","generated_at":"2026-06-06T04:15:59.965368+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Skye Bioscience raises $46.2M, sells real estate; equity now $49M for Nasdaq compliance","bullets":["Net proceeds of ~$46.2M from private placement of 11.7M shares and pre-funded warrants on Jan 31, 2024.","Subsidiary Avalite Sciences sold real estate on Jan 19, 2024, contributing ~$1.14M gain to equity.","Pro forma stockholders' equity as of Sept 30, 2023 adjusted to $49.05M from $1.70M.","Company believes equity now exceeds $5M minimum required for initial listing on The Nasdaq Capital Market."],"urls":{"canonical":"https://secwatch.observer/filing/0001516551-24-000008","json":"https://secwatch.observer/filing/0001516551-24-000008.json","markdown":"https://secwatch.observer/filing/0001516551-24-000008.md","text":"https://secwatch.observer/filing/0001516551-24-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1516551/000151655124000008/0001516551-24-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1516551/000151655124000008/skye-20240212.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T04:15:59.965368+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}